Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Company has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments. These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA. NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression.
$RGBP
Couscous is a crook and an inveterate liar who has in the past killed several companies. You have to be stupid to still believe this big pig who puts out bogus PRs for naive and gullible traders.....LOOOOL !!!
A compensation to promote this stock is going to be huge for every long here, maybe sooner than expected
How much are you being compensated to promote this fraudulent garbage?
News: Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program $RGBP @TheRegenBio #mRNA #autoimmunity #FDA #pfizer $PFE #NEWS
NEWS PROVIDED BY
Regen BioPharma Inc.
25 Oct, 2023, 09:30 ET
Autoimmunity to be Targeted
SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html) while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html.
The Company has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments. These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA. NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression.
"Being able to substantially elevate NR2F6 levels is truly an unexpected, but welcome finding. We now have a sound scientific basis to pursue designing T cells which can tamp down on the uncontrolled immune activation seen in multiple autoimmune disorders," says Dr. Harry Lander, Chief Scientific Consultant to the Company. "We recently filed a patent application around such T cells and we feel we have a head start on this in the scientific community, particularly around using nuclear receptors such as NR2F6."
"Having a second confirmatory study gives us confidence we are making the right decision to pursue these novel cell therapies focused on autoimmunity," says Dr. David Koos, Chairman and CEO of the company. "I expect that after consulting with our Board of Advisors and internally, the Company will soon have a clear picture of the specific indications and approaches it will pursue."
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION:
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Email: david.koos@regenbiopharmainc.com or david.koos@regenbiopharma.com
Twitter (now X): https://twitter.com/TheRegenBio
SOURCE Regen BioPharma Inc.
https://www.prnewswire.com/news-releases/regen-biopharma-inc-receives-second-phase-confirmatory-data-on-its-duracar-car-t-cell-therapy-program-301967324.html
It's trading at its 10-day average volume as lunchtime approaches on today's News... UP almost 14%. Looking good.
$RGBP
Been awhile since I’ve seen this one, did this have a reverse split to get over $1? Last I saw this it was a trip zero stock.
OMG MOAR GREAT NEWS THAT WILL CATAPULT THIS TURD TO DA MOON!
Let me once again explain that pre clinical lab testing generating a pre determined outcome is about as meaningful as Koos' bowel movements after a night of him eating taco bell. These tests tell us nothing. Koos will never get any of this into true in vivo clinical trials. He's a failure just as those promoters trying to pump the share price up with their vapid posts.
https://finance.yahoo.com/news/regen-biopharma-inc-receives-second-133000496.html
Another friendly reminder that all of the great things that the promoters promised were going to happen never did. There has only been one person that has been right about this turd and konman of a CEO for years now...and that has been me. And remember how Koos told his investors that a reverse split needed to happen because his investors told him that without it, he wouldn't get funding. Well, those investors never did invest in the company after the reverse split. Some "business leader" Koos is, amirite?
Keep posting the pumperdumper news! It is Working! Look how the pps is sky rocketing!
RGBP plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, RGBP is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. RGBP is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
$RGBP Great Article out: Development Data for mRNA & Small Molecule Immunotherapies for Treating Cancer: Regen BioPharma,: Stock Symbol: RGBP
https://apnews.com/press-release/ein-presswire-newsmatics/gene-therapy-cancer-preventive-care-aa5091e545b2018757bbf6e85cc3468b
$RGBP Agreed looking for that move on the chart.
This is a trash stock run by a konman. Where is that white paper that David paid his gyno brother $300K for? Where is that capital raise David said would happen if he did the reverse stock split?
What a joke. The fat bastard now has a few paid posters on here trying to get the pps back to $2.
The con is back on!
$RGBP Regen BioPharma, Inc. Expects Second Phase of Confirmatory Study Shortly https://finance.yahoo.com/news/regen-biopharma-inc-expects-second-120000951.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
"We know our shareholders are anxious to hear about our results surrounding modifying NR2F6 levels in CAR T-cells and we will get this data out as soon as we can," says Dr. David Koos, Chairman and CEO of the company.
"A second unrelated CRO is currently performing qRT-PCR tests to determine if NR2F6 mRNA is elevated or inhibited by our CAR in T-Cells," says Dr. Harry Lander, Chief Scientific Consultant to the Company." If NR2F6 mRNA is suppressed (stimulating certain immune functions) then this product shows potential for treatment of cancer and if NR2F6 mRNA is elevated (suppressing certain immune functions) then the product shows potential for treatment of autoimmune disorders."
Too funny and quoting pumper stumper...must be a joke
Oh how I love the smell of desperation in the morning when the goobers post the same spam multiple times.
They’re “scared” all right- scared of the short squeeze & scared their masters won’t pay them for their repetitive spam.
LMAO
O11
Regen BioPharma Inc (RGBP)
Post#
112058
of 118128
pumper_stumper
Re: None
Friday, 08/12/2022 2:28:53 PM
"David Koos Scares Me - I just dumped all my shares. I should have done more research into the CEO and the company. It may get pumped again and some may make a little, but this whole thing seems to scammy for my money.
I bought RGBP because they made a deal with OPNH. I really thought they had something... I really wanted this stock to work out. Taking my loss...
You can google "david koos scam" and find all kinds of information.
In 2005, he was part of GISBeX offshore stock exchange scam. He got out early neough to no bet prosecuted. He did not serve jail time, but others did. https://www.sandiegoreader.com/news/2005/mar/17/penny-swindlers/
It is alarming how man issues this Koos guy has run into. I have no idea how I missed it. (https://casetext.com/case/starcity-capital-llc-v-bio-matrix-scientific-grp)
The item that caught my eye is that he is a CEO of two companies and they both made deals with OPNH. I am not sure how it is all connected, but again seems sketchy.
I hope you all the best, but proceed with caution and do a few google searches."
- From a former shareholder!
https://www.sandiegoreader.com/news/2005/mar/17/penny-swindlers/
https://casetext.com/case/starcity-capital-llc-v-bio-matrix-scientific-grp/
https://www.otcmarkets.com/stock/ONPH/news/Oncology-Pharma-Signs-Worldwide-Licensing-Agreement-with-Sybleu-Inc-for-Commercialization-of-Chemotherapeutic-Agent-in-C?id=291550
https://www.streetinsider.com/dr/news.php?id=20958272
https://www.nanalyze.com/2014/03/big-red-flags-from-bio-matrix-and-regen-biopharma/
Regen BioPharma Inc (RGBP)
Post#
112058
of 118128
pumper_stumper
Re: None
Friday, 08/12/2022 2:28:53 PM
"David Koos Scares Me - I just dumped all my shares. I should have done more research into the CEO and the company. It may get pumped again and some may make a little, but this whole thing seems to scammy for my money.
I bought RGBP because they made a deal with OPNH. I really thought they had something... I really wanted this stock to work out. Taking my loss...
You can google "david koos scam" and find all kinds of information.
In 2005, he was part of GISBeX offshore stock exchange scam. He got out early neough to no bet prosecuted. He did not serve jail time, but others did. https://www.sandiegoreader.com/news/2005/mar/17/penny-swindlers/
It is alarming how man issues this Koos guy has run into. I have no idea how I missed it. (https://casetext.com/case/starcity-capital-llc-v-bio-matrix-scientific-grp)
The item that caught my eye is that he is a CEO of two companies and they both made deals with OPNH. I am not sure how it is all connected, but again seems sketchy.
I hope you all the best, but proceed with caution and do a few google searches."
- From a former shareholder!
https://www.sandiegoreader.com/news/2005/mar/17/penny-swindlers/
https://casetext.com/case/starcity-capital-llc-v-bio-matrix-scientific-grp/
https://www.otcmarkets.com/stock/ONPH/news/Oncology-Pharma-Signs-Worldwide-Licensing-Agreement-with-Sybleu-Inc-for-Commercialization-of-Chemotherapeutic-Agent-in-C?id=291550
https://www.streetinsider.com/dr/news.php?id=20958272
https://www.nanalyze.com/2014/03/big-red-flags-from-bio-matrix-and-regen-biopharma/
Regen BioPharma Inc (RGBP)
Post# 112058 of 118128
pumper_stumper
Re: None
Friday, 08/12/2022 2:28:53 PM
"David Koos Scares Me - I just dumped all my shares. I should have done more research into the CEO and the company. It may get pumped again and some may make a little, but this whole thing seems to scammy for my money.
I bought RGBP because they made a deal with OPNH. I really thought they had something... I really wanted this stock to work out. Taking my loss...
You can google "david koos scam" and find all kinds of information.
In 2005, he was part of GISBeX offshore stock exchange scam. He got out early neough to no bet prosecuted. He did not serve jail time, but others did. https://www.sandiegoreader.com/news/2005/mar/17/penny-swindlers/
It is alarming how man issues this Koos guy has run into. I have no idea how I missed it. (https://casetext.com/case/starcity-capital-llc-v-bio-matrix-scientific-grp)
The item that caught my eye is that he is a CEO of two companies and they both made deals with OPNH. I am not sure how it is all connected, but again seems sketchy.
I hope you all the best, but proceed with caution and do a few google searches."
- From a former shareholder!
https://www.sandiegoreader.com/news/2005/mar/17/penny-swindlers/
https://casetext.com/case/starcity-capital-llc-v-bio-matrix-scientific-grp/
https://www.otcmarkets.com/stock/ONPH/news/Oncology-Pharma-Signs-Worldwide-Licensing-Agreement-with-Sybleu-Inc-for-Commercialization-of-Chemotherapeutic-Agent-in-C?id=291550
https://www.streetinsider.com/dr/news.php?id=20958272
https://www.nanalyze.com/2014/03/big-red-flags-from-bio-matrix-and-regen-biopharma/
Regen BioPharma Inc (RGBP)
Post# 112058 of 118128
pumper_stumper
Re: None
Friday, 08/12/2022 2:28:53 PM
"David Koos Scares Me - I just dumped all my shares. I should have done more research into the CEO and the company. It may get pumped again and some may make a little, but this whole thing seems to scammy for my money.
I bought RGBP because they made a deal with OPNH. I really thought they had something... I really wanted this stock to work out. Taking my loss...
You can google "david koos scam" and find all kinds of information.
In 2005, he was part of GISBeX offshore stock exchange scam. He got out early neough to no bet prosecuted. He did not serve jail time, but others did.
https://www.sandiegoreader.com/news/2005/mar/17/penny-swindlers/
It is alarming how man issues this Koos guy has run into. I have no idea how I missed it. (https://casetext.com/case/starcity-capital-llc-v-bio-matrix-scientific-grp)
The item that caught my eye is that he is a CEO of two companies and they both made deals with OPNH. I am not sure how it is all connected, but again seems sketchy.
I hope you all the best, but proceed with caution and do a few google searches."
- From a former shareholder!
https://www.sandiegoreader.com/news/2005/mar/17/penny-swindlers/
https://casetext.com/case/starcity-capital-llc-v-bio-matrix-scientific-grp/
https://www.otcmarkets.com/stock/ONPH/news/Oncology-Pharma-Signs-Worldwide-Licensing-Agreement-with-Sybleu-Inc-for-Commercialization-of-Chemotherapeutic-Agent-in-C?id=291550
https://www.streetinsider.com/dr/news.php?id=20958272
https://www.nanalyze.com/2014/03/big-red-flags-from-bio-matrix-and-regen-biopharma/
pre clinical lab tests to confirm pre clinical lab tests.
This is routine in pre clinical testing and hardly something to put out a pr UNLESS you are a STINKY PINKY trying to pump up your pathetic pps.
Koos is the classical OTC scam artist CEO.
His pathetic track record with his public companies should be a warning to others but there are always those that love to gamble on scam artist run OTC companies in the hope of making a quick buck.
Regen BioPharma, Inc. Expects Second Phase of Confirmatory Study Shortly
SAN DIEGO, Oct. 18, 2023 PRNewswire
Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels in human T cells. The Company has recently received unexpected and potentially extremely useful data from one of its contract research organizations (CRO) retained to perform experimental studies on the Company's DuraCAR CAR T-cell therapeutic. These studies demonstrated that T cells which express the chimeric antigen receptor (CAR) construct expressing siRNA for NR2F6 can be successfully created.
"A second unrelated CRO is currently performing qRT-PCR tests to determine if NR2F6 mRNA is elevated or inhibited by our CAR in T-Cells," says Dr. Harry Lander, Chief Scientific Consultant to the Company." If NR2F6 mRNA is suppressed (stimulating certain immune functions) then this product shows potential for treatment of cancer and if NR2F6 mRNA is elevated (suppressing certain immune functions) then the product shows potential for treatment of autoimmune disorders."
Once the Company receives the data, it will analyze the results and report the findings in a press release in order to keep the company's shareholders informed of its progress.
"We know our shareholders are anxious to hear about our results surrounding modifying NR2F6 levels in CAR T-cells and we will get this data out as soon as we can," says Dr. David Koos, Chairman and CEO of the company.
Warning !!!
Thomas Ichim who produced more than 80% of RGBP's "patents" turns out to be a crook just like the CEO of Regen Biopharma the lying crook David Koos.
$*SOI ***ATTENTION ALL INVESTORS WHO WERE SCAMMED BY CEO TIM DIXON and Thomas Ichim**** As most of you know we have been scammed by CEO Tim Dixon. I would encourage you all to submit a "tip" with the SEC and spread the word. Do not let this crock of turd CEO get away with this crap. It's time to make him pay as we all have believed his lie after lie after lie. Here is the link which I will post daily. Its time. https://www.sec.gov/whistleblower/submit-a-tip This is one way to possibly get paid back by the SEC as a whistleblower!
**FRAUD ALERT**** as most with any sort of common cents knows this is a scam. Has been for well over a decade. Lie upon lie the only real truth is this is a share selling operation run by career criminals CEO Tim Dixon and Thomas Ichim a crackhead. Continue to report their mangy asses to the SEC. I mean...... those are the actual facts.
$TSOI is understandably around historic lows and 99% loss of "value"
💩 Leadership is dishonest + extremely unprofessional scumbags
💩 IP is being diluted/sold for peanuts across 8 SCAM Subsidiaries
💩 NO clinical trials registered as current (15+ years in existence)
💩 Very little cash on hand
💩 No FDA Phase III IND (couldn't afford it)
💩 Grossly limited funding (stock given away at 20% discount)
💩 Substantial/ongoing dilution
💩 Uses RTT to cloak chronic incompetence & BS while touting lifesaving work. Yet they can't get an actual clinical study registered to save their own life.
💩 Homophobic, narcissistic CEO calls shareholders "pigs" and mocks dead mothers
💩 Only 4 granted patents (most of which are related to blueberry/broccoli pills with crappy sales)
💩 Pathetic/decreasing revenue
💩 Beaver-infested company land (that
CEO squats on)
💩 Dumbest gaggle of paid pumper clowns on ST's
💩 Insiders never buy shares
💩 Stuck in lawsuits
I have no short position here.
Now just answer the question.
How much are you being compensated to promote Regen?
$RGBP #Shortsqueeze. How huge is your short position?
How much are you being compensated to promote this fraudulent shit?
$RGBP has news to talk about and it gets posted on the message board.
Riddle me this JJ, why is it that those who were "pushing" this stock, telling us what a great company Regen is with its billion dollar patent portfolio and business genius and leader with CEO David Koos stopped "pushing" it and posting on here once the Reverse split was announced?
I'll tell you. Because it is easier to manipulate a stock when it is trading at a fraction of a penny than when it is trading for over a dollar.
The PND crowd knows that it is much harder to manipulate a higher priced stock with a much lower float. There is no liquidity in doing that.
So that comes back to why there is now a push to try this again? Albeit there seems to be only two true believers trying to do so but what's the catch?
Not true. What is true? You are constantly spamming the board with fear, uncertainty and doubt for the short positions you manage.
Not the "New Research Report on Regen Biopharma " Story Again
$RGBP Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc. https://www.wsj.com/articles/goldman-small-cap-research-publishes-new-research-report-on-regen-biopharma-inc-fe695ae1?reflink=mw_share_twitter
nothing_of_value_ever_gets_in_or_out---only_the_scabs_on_his_face
rgbp--->koosimodo's_trust-free_zone's_ironclad
Hi jedijazz. Promote endless stock scams much?
Not the Car-Tcell therapy story again
Not the Car-Tcell therapy story again
It's disturbingly hilarious that this Clown has a share price of a 1.80 ,who is corrupt and does pretty much nothing . And actual companies conducting clinical studies and phase trials , struggle to stay sec compliant with a share price above a dollar for Nasdaq. Of course share structure and other circumstances play a roll in it but , it's just sad
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
FN Media Group LLC
Thu, October 12, 2023 at 9:00 AM EDT
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, which are expected to offer lucrative opportunities for market expansion and flourishing opportunities. The rise in awareness and upsurge in approvals of new CAR T-cell therapies and promising advanced drugs present in pipelines are anticipated to offer remunerative opportunities for the expansion for the global CAR T-cell therapy market in the near future. Some of the benefits of CAR T-cell therapies over conventional drugs, include the destruction of cancer cells using patients' immune system, early recovery, and shortened treatment time. In addition, CAR T-cell therapy survives for a long time in the body, as they have the ability to recognize and target cancer cells even if the cancer relapses. According to a report released by Precedence Research, the global cell therapy market was valued at US$ 12 billion in 2022 and it is expected to hit US$ 83.78 billion by 2032, poised to grow at a CAGR of 21.50% during the forecast period 2023 to 2032. Further, an additional report by Allied Market Research stated the global car t-cell therapy market size was valued at $1.7 billion in 2021, and is projected to reach $6.1 billion by 2031. Active biotech and pharma companies in the markets this week include Amgen (NASDAQ:AMGN), Regen BioPharma, Inc. (OTCPK:RGBP), Gilead Sciences, Inc. (NASDAQ:GILD), GSK plc (NYSE:GSK), Incyte (NASDAQ:INCY).
Precedence Research added: “The growth of global cell therapy market is attributed to the rising incidents of chronic disorders and infections. In addition, the growing cases of diabetes are also boosting the market growth. As per the International Diabetes Federation Diabetes Altas, almost 573 million persons globally had diabetes in 2022, with the number anticipated to grow by 643 million by 2032 and 783 million by 2045. Moreover, the growing number of research studies and clinical trials are also boosting the growth of global cell therapy market. One of the key factors propelling the expansion of global cell therapy market is adoption of innovative and latest technologies. Furthermore, after the impact of COVID-19 pandemic, the market for cell therapy is growing at a rapid pace. With over 900 companies working on advanced therapeutics around the world and around 1,000 cell or gene therapy clinical studies now conducted, the cell therapy market might see a surge in number of approvals. According to industry experts, up to 60 new cell therapies could be developed in the next few years, curing around 350,000 patients in the U.S. alone.”
Regen BioPharma, Inc. Receives First Phase of Confirmatory Study - Regen BioPharma, Inc. (OTCPK:RGBP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders.
The company has now received the first set of confirmatory data which demonstrates that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 were successfully created. In addition, the siRNA that is designed into the CAR T-cell was very highly expressed. Subsequent studies will determine if the expression of NR2F6 mRNA is suppressed or enhanced as a result of the high expression of siRNA.
"This is a major accomplishment in moving this model forward into therapies because in order to test whether we can genetically manipulate NR2F6 levels, we have to be able to produce a CAR T-cell where we demonstrate expression of this siRNA," says Dr. Harry Lander, Chief Scientific Consultant to the company. "We are excited to see the results on NR2F6 expression. If it is inhibited, we will focus on using these DuraCAR cells as originally envisioned - to attack solid tumors. If it is enhanced, we will begin re-tooling these cells to treat autoimmune disorders."
"We are delighted to get our first dataset from an independent CRO which shows that the CAR T-cells are doing what we expect and look forward to the next set of data which will inform us about the disease areas, whether autoimmunity or cancer, we will focus on," says Dr. David Koos, Chairman and CEO of the company. CONTINUED… Read this full press release and more news for RGBP at: https://regenbiopharmainc.com/company-news1/
Media Contact email: editor @
SOURCE Financialnewsmedia.com
OMG! LIKEOMG! ThIS iS HuGe NeWs! https://finance.yahoo.com/news/global-car-t-cell-therapy-130000592.html
Don't forget to let us know that Reject Bio's patents are worth billions and that Koos is a "business leader!"
Followers
|
1052
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
118384
|
Created
|
09/03/14
|
Type
|
Free
|
Moderators Huggy Bear SmellMyFinger |
0.000x Ticker Symbol: RGBP
Barchart
All other Regen BioPharma News
https://www.regenbiopharmainc.com/company-news.html
Date | Outsanding Shares | Reason for Issue |
---|---|---|
12/31/21 | 4,564,002,832 | |
3/28/22 | 4,580,002,832 | Debt and Interest |
4/7/22 | 4,736,002,832 | Debt and Interest |
5/16/22 | 4,820,002,832 | Debt |
7/1/22 | 4,920,002,832 | Debt |
7/17/22 | 4,970,002,832 | Debt and Interest |
8/1/22 | 5,024,517,324 | Debt |
8/4/22 | 5,031,517,324 | EXPENSES |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |